midatech is a world leader in the design, synthesis and manufacture of biocompatible gold nanoparticles (gnps) with a core focus on therapeutics for diabetes and cancer. midatech has a strong pipeline of product candidates in clinical and pre-clinical development for the treatment of diabetes and various cancers. in 2012, midatech established midasol therapeutics lp, a strategic joint venture with monosol rx llc to focus on the development and commercialization, via partnering or licensing, of products primarily for the treatment of diabetes. midasol’s lead product, midaform™ insulin pharmfilm, is a unique product for the oral delivery of insulin in diabetic patients and will enter phase ii clinical studies in 2014. these technologies are also being evaluated in the diabetes area by a major us pharmaceutical company. midatech’s unique gnp technology enables the administration and targeted delivery of therapeutic compounds to specific cells and tissues. multiple drug molecules can b
Company profile
Ticker
BDRX
Exchange
Website
CEO
Stephen Anthony Stamp
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Midatech Pharma Plc
SEC CIK
BDRX stock data
Latest filings (excl ownership)
6-K
Preliminary Results for the Year Ended 31 December 2023
19 Apr 24
20-F
2023 FY
Annual report (foreign)
18 Apr 24
424B3
Prospectus supplement
28 Mar 24
EFFECT
Notice of effectiveness
28 Mar 24
F-1
Registration statement (foreign)
18 Mar 24
424B3
Prospectus supplement
28 Feb 24
424B3
Prospectus supplement
28 Feb 24
424B3
Prospectus supplement
28 Feb 24
6-K
Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update
23 Feb 24
6-K
Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024
22 Jan 24
Transcripts
Latest ownership filings
SC 13G/A
Ionic Ventures, LLC
14 Feb 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
CVI Investments, Inc.
14 Feb 24
SC 13G/A
Cavalry Fund I LP
13 Feb 24
SC 13G
Bigger Capital, LLC
12 Feb 24
SC 13G
Mercer Street Global Opportunity Fund, LLC
8 Jan 24
SC 13G
Cavalry Fund I LP
28 Dec 23
SC 13G
Ionic Ventures, LLC
6 Mar 23
SC 13G
CVI Investments, Inc.
21 Feb 23
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 23
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 7 |
Opened positions | 2 |
Closed positions | 4 |
Increased positions | 0 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 77.17 mm |
Total shares | 28.88 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
IOI Ionic Ventures | 18.04 mm | $11.36 mm |
CVI Investments | 10.83 mm | $6.88 mm |
Susquehanna International | 11.74 k | $57.16 mm |
Rhumbline Advisers | 223.00 | $1.09 mm |
UBS UBS Group AG - Registered Shares | 71.00 | $354.00 k |
Tower Research Capital | 51.00 | $254.00 k |
MS Morgan Stanley | 16.00 | $80.00 k |
Proequities | 0.00 | $0.00 |
News
12 Health Care Stocks Moving In Wednesday's Intraday Session
3 Apr 24
12 Health Care Stocks Moving In Friday's Intraday Session
29 Mar 24
12 Health Care Stocks Moving In Friday's Pre-Market Session
29 Mar 24
12 Health Care Stocks Moving In Thursday's After-Market Session
28 Mar 24
Crude Oil Surges Over 2%; MSC Industrial Shares Fall After Q2 Results
28 Mar 24
Press releases
Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers
28 Mar 24
Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone
1 Mar 24
Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update
23 Feb 24
This Biotech Shares Are Up Following 9.9% Institutional Stake Disclosure
13 Feb 24
Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients
8 Feb 24